Compare · NMTC vs RMD
NMTC vs RMD
Side-by-side comparison of NeuroOne Medical Technologies Corporation (NMTC) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NMTC and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $32.03B, about 796.4x NMTC ($40.2M).
- NMTC has been more active in the news (6 items in the past 4 weeks vs 2 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 4 for NMTC).
- Company
- NeuroOne Medical Technologies Corporation
- ResMed Inc.
- Price
- $4.75-0.52%
- $219.82+0.11%
- Market cap
- $40.2M
- $32.03B
- 1M return
- +2.68%
- -
- 1Y return
- +26.03%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 2
- Recent ratings
- 4
- 25
NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. NeuroOne Medical Technologies Corporation has a strategic partnership with RBC Medical Innovations to develop and manufacture a radiofrequency generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NMTC
- SEC Form SCHEDULE 13G filed by NeuroOne Medical Technologies Corporation
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 4 filed by Mills Jason Richard
- SEC Form 4 filed by Mathiesen Jeffrey S
- SEC Form 4 filed by Buckman Paul
- SEC Form 4 filed by Andrle Edward
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Christianson Mark
- SEC Form 4 filed by Mertens Steve
- SEC Form 4 filed by Rosa David A
Latest RMD
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)
- Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)
- SEC Form 144 filed by ResMed Inc.